Lp(a) and Cardiovascular Risk: Advancing Awareness, Testing, and Management in Clinical Practice : Episode 14
Opinion
Video
Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
Author(s):
Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.
Video content above is prompted by the following:
- How might knowledge of Lp(a) levels empower patients in their management of ASCVD risk factors?
- How might providers partner with their patients with respect to Lp(a) testing and ASCVD risk management?
- What value might improved ASCVD risk assessment and risk factor management offer on a population level, such as to a health care system?
- The NLA recommends Lp(a) testing only once in a patient’s lifetime. How, if at all, might this frequency benefit health systems?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
